| SPEAKER | TITLE | TIME |
| Francesca Buttini (University of Parma) Cornelia Désirée Sonntag |
Conference Opening | 9:00-9:10 |
NEW PARADIGMS IN LUNG DELIVERY
|
||
| David Edwards (Harvard University, US) |
Title TBA | 9:10-9:40 |
| Michael Hindle (Virginia Commonwealth University, US) |
Development of a Lung Surfactant Powder Aerosol Product for Babies with Respiratory Distress Syndrome |
9:40-10:05 |
| Pavan Muttil (University of New Mexico, US) |
Formulation Development and Preclinical Evaluation of Aerosol Vaccines: Challenges, Opportunities and Lessons Learnt |
10:05-10:30 |
| To be selected from abstracts submitted | 10:30-10:45 | |
|
COFFEE BREAK + POSTER SESSION |
||
| Nicola Tsapis (Paris-Saclay University, France) |
Nanomedicines and microparticles for the treatment of pulmonary infections |
11:25-11:50 |
| David Cipolla (Insmed, USA) | Preclinical and CMC Development of Treprostinil Palmitil Inhalation Powder (IPF) |
11:50-12:15 |
| Paul Hagedoorn (University of Groningen, The Netherlands) |
The development of pulmonary levodopa applications for patients with Parkinson’s disease |
12:15-12:40 |
|
LIGHT LUNCH + POSTER SESSION |
||
RESPIRATORY TREE AS A SITE FOR THE DELIVERY OF BIOLOGICS
|
||
| Tomaso Guidi (Chiesi, Italy) |
Inhaled Biologics: current trends in the industry |
14:20-14:40 |
| Francesca Buttini (University of Parma, Italy) |
The formulation of protein and probiotics in dry powder inhalers |
14:40-15:05 |
| To be selected from abstracts submitted | 15:05-15:20 | |
| To be selected from abstracts submitted | 15:20-15:35 | |
|
COFFEE BREAK + POSTER SESSION |
||
| Regina Scherließ (Kiel University, Germany) |
Nasal vaccine technology | 16:15-16:40 |
| Ben Forbes (King’s College, UK) |
Biologics from nose to brain | 16:40-17:05 |
| To be selected from the abstract submitted | 17:05-17:20 | |
|
WELCOME RECEPTION |
||
| SPEAKER | TITLE | TIME |
BIOLOGICS LOVE LUNGS
|
||
| Hugh Smyth (University of Texas at Austin, US) |
Developing inhaled mAbs and nucleic acids for therapeutic success |
9:00-9:30 |
| Jenny Lam (UCL, UK) |
How to make antibodies formulation stable and inhalable |
9:30-9:55 |
| To be selected from abstracts submitted | 9:55-10:10 | |
| To be selected from abstracts submitted | 10:10-10:25 | |
|
COFFEE BREAK + POSTER SESSION |
||
ENVIRONMENTAL PROTECTION BECOMES A REALITY IN THE DEVELOPMENT OF PMDI
|
||
| Barzin Gavtash (Kindeva, UK) |
Atomization properties and aerosol characteristics of new low GWP propellants |
11:05-11:30 |
| TBA (Chiesi, Italy) |
Re-formulation of pMDI in HFA152a | 11:30-11:55 |
| David Lecthuga (Astra Zeneca, US) |
pMDI: stable suspension in HFO1234ze | 11:55-12:20 |
| TBA RxPack (Italy) |
Re-formulation of beclomethasone diproprionate ethanol-based solution in new eco-sustainable propellants |
12:20-12:35 |
|
LIGHT LUNCH + POSTER SESSION |
||
LAST FRONTIERS IN LUNG INFECTION
|
||
| Keertan Dheda (University of Cape Town, South Africa) |
The challenges and management of multidrug-resistant tubercolosis |
14:20-14:45 |
| Lea Ann Daily (University of Vienna, Austria) |
A liposomal strategy for inhaled bedaquiline: in vivo pharmacodynamics and pharmacokinetics | 14:45-15:10 |
| Francesca Ungaro (University of Naples, Italy) |
Novel formulation approaches for lung infection treatment |
15:10-15:35 |
| Mirjam Kobler (H&T Presspart, UK) |
The Sunriser – achieving high performance in challenging formulations |
15:35-15:50 |
|
GALA DINNER |
||
| SPEAKER | TITLE | TIME |
NEW RESEARCH
|
||
| Federico Lavorini (University of Florence, Italy) |
Physiological and Technological barriers in the treatment of COPD |
9:00-9:30 |
| Jan de Backer (FLUIDDA, USA) |
The role of digital twins and in-silico trials as regulatory tools for the authorization of orally inhaled drugs |
9:30-9:55 |
| Carsten Ehrhardt (Trinity College, Ireland) |
Uptake mechanisms of molecules released into the lungs |
9:55-10:20 |
|
COFFEE BREAK + POSTER SESSION |
||
| Daniela Traini (Macquarie University, Australia) |
Non-Clinical Tests in the Evaluation of Inhaled Pharmaceuticals |
11:00-11:25 |
| Per Backmann (Emmace, Sweden) |
Physiologically-based biopharmaceutical models- a tool to understand local and systemic exposure of inhaled medicines |
11:25-11:50 |
| Amrit Paudel (RCPE, Austria) |
Empowering drug-drug co-amorphous inhaled formulation design using datadriven approach |
11:50-12:15 |
|
CLOSING REMARKS |
||
